Chinese pharmaceutical group set to acquire Imexpharm
Imexpharm Corporation announced that it has received a public bid offer for nearly 78% of its shares from Lian SGP Holding Pte. Ltd., a subsidiary fully owned by China’s Livzon Pharmaceutical Group Inc.
The estimated value of this acquisition deal is approximately VND6.9 trillion (US$262.6 million).
As detailed in a report released on January 15, the bid involves the purchase of 120 million shares, which corresponds to 77.94% of Imexpharm's charter capital and about 77.96% of its total voting shares.
Lian SGP has proposed a purchase price of VND57,400 per share, which indicates the group's robust commitment to expanding its footprint in the Vietnamese pharmaceutical market.
This acquisition signals a significant investment intent by Livzon Pharmaceutical, a well-established player in the pharmaceutical sector.
Back in May 2025, the company expressed plans to acquire shares from three major shareholders: SK Investment, which holds 47.69% of Imexpharm; Binh Minh Kim Investment JSC with 9.75%; and KBA Investment JSC with 7.37%.
Initially, the share transfer was expected to encompass 64.81% of Imexpharm’s equity, although the current bid represents a greater percentage.
Imexpharm has demonstrated solid growth, reporting a net revenue of over VND2.2 trillion over the first 11 months of 2025, which is a 14% year-on-year increase. Profits before tax have also surged, rising by 15% on-year to reach VND410 billion.
On the stock market, shares of Imexpharm closed January 15 at VND53,700 a share, showing positive movement over the past week.
Vietnam's pharmaceutical market sees major M&A deal
The Vietnamese pharmaceutical sector has recently witnessed one of its largest mergers and acquisitions (M&A) to date, with Livzon Pharmaceutical Group Inc. of China acquiring approximately 64.81% of Imexpharm Pharmaceutical Joint Stock Company (IMP).
